Practical aspects of cosmetic botulinum toxin

International Ophthalmology Clinics

Volumn 45, Issue 3, 2005, Pages 99-106

  Mannor, Geva E ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; NEUROTOXIN; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PENICILLAMINE; QUINOLONE DERIVATIVE;

ANATOMY; BOTULISM; BOTULISM LIKE ILLNESS; CONSULTATION; DILUTION; DIPLOPIA; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG INDICATION; DRUG OVERDOSE; DRUG POTENCY; DRUG RECONSTITUTION; DRUG SAFETY; DRUG STORAGE; DRY EYE; DYSPHAGIA; ECTROPION; ELECTROMYOGRAPHY; ERYTHEMA; ESTHETICS; FACE; FACE DEFORMITY; FATIGUE; HEADACHE; HEART DEATH; HEMIFACIAL SPASM; HUMAN; IMMUNOGENICITY; INFLUENZA; LACRIMATION; LAGOPHTHALMOS; MALAISE; METALLIC TASTE; MUSCLE WEAKNESS; MYASTHENIA; NAUSEA; PAIN; PATIENT ATTITUDE; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PTOSIS; REJUVENATION; REVIEW; SPEECH DISORDER; STRABISMUS; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; WRINKLE;

BEAUTY CULTURE; BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; FACIAL MUSCLES; HUMANS; NEUROMUSCULAR AGENTS; OCULOMOTOR MUSCLES; SKIN AGING;

EID: 22544465599     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000167160.48750.94     Document Type: Review

References (68)

1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci. 1973;12:924-929.
2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-1048.
3. American Academy of Ophthalmology. Botulinum toxin therapy of eye muscle disorders: safety and efficacy. Ophthalmology. 1989;96:37-43.
4. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of 3 controlled trials. Neurology. 2000;55:529-535.
5. Carruthers JDM, Carruthers A. Treatment of glabellar frown lines with C. botulinum toxin-a exotoxin. J Dermatol Surg Oncol. 1992;18:17-22.
6. Keen MS, Blitzer A, Aviv JE, et al. Botulinum toxin for the treatment of functional lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119:1018-1021.
7. Keen MS, Blitzer A, Aviv JE, et al. Botulinum toxin for hyperkinetic facial lines: results of a double-blind placebo-controlled study. Plast Reconstr Surg. 1994;94:95-99.
8. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, vehicle-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996;35:569-572.
9. Carruthers JA, Lowe N, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
10. Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. Vet Hum Toxicol. 2002;42:163-166.
11. Bakheit AM, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injection of botulinum toxin type A: a report of 2 cases [letter]. J Neurol Neurosurg Psychiatry. 1997;62:198.
12. Simpson LL. Botulinum Neurotoxin and Tetanus Toxin. London: Academic Press; 1989.
13. Jankovic J, Hallet M. Therapy With Botulinum Toxin. New York: Marcel Dekker; 1994.
14. Moore AP. Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Science; 1995.
15. Huang W, Foster JA, Rogachesfky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43:249-259.
16. Blitzer A, Binder WJ, Boyis JB, et al. Management of Facial Lines and Wrinkles. Philadelphia: Lippincott Williams & Wilkins; 2000.
17. Lowe NJ, Carruthers A, Carruthers J, et al. Textbook of Facial Rejuvenation: The Art of Minimally Invasive Combination Therapy. London: Martin Dunitz; 2002.
18. Carruthers A, Carruthers JDA. Using Botulinum Toxins Cosmetically. London: Martin Dunitz; 2003.
19. Klein AW. Complications, adverse reactions and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549-556.
20. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injections in the monkey. Mov Disord. 1988;3:33-38.
21. Bhatia KP, Munchau A, Thompson PD, et al. Generalized muscular weakness after botulinum toxin injections for dystonia: a report of 3 cases. J Neurol Neurosurg Psychiatry. 1999;67:90-93.
22. Tugnoli Y, Eleopra R, Quatrale R, et al. Botulism-like syndrome after BTX-A for local hyperhydrosis. Br J Dermatol. 2002;147:8080.
23. Klein AW. Complications with the use of botulinum toxin. Dermatol Clin. 2004;22: 197-205.
24. Murray C, Solish N. Metallic taste: an unusual reaction to botulinum toxin A. Dermatol Surg. 2003;29:562-563.
25. Alam M, Arndt K, Dover J. Severe, intractable headache after injection with botulinum A exotoxin: a report of 5 cases. J Am Acad Dermatol. 2002;46:62-65.
26. Matarasso A, Deva AK. Safety and efficacy report: botulinum toxin. Plast Reconstr Surg. 2003;112(5 suppl):55S-65S.
27. Carruthers J, Fagien S, Matarasso SL, et al. Consensus recommendations in the use of botulinum toxin a in facial aesthetics. Plast Reconstr Surg. 2004;114(6 suppl):1S-22S.
28. Almeida AT, Kadunc BV, di Chiacchio N, et al. Foam during reconstitution does not affect the potency of botulinum toxin type a. Dermatol Surg. 2003;29:530-532.
29. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24:1179-1180.
30. Alam M, Dover J, Arndt K, Pain associated with injection of botulinum exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol. 2002;138:510-514.
31. Gassner HG, Sherris DA. Addition of anesthetic agent enhances the predictability of botulinum toxin injection. Mayo Clin Proc. 2000;75:701-704.
32. Gartan MG, Hoffman HT. Crystalline preparation of botulinum toxin type a (BTX): degradation in potency with storage. Otolaryngol Head Neck Surg. 1993;108:135-140.
33. Van Laborde S, Dover J, Moore M, et al. Reduction in pain with botulinum toxin type B diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol. 2003;48:875-877.
34. McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type a toxin: factors affecting potency. Toxicon. 1996;34:75-85.
35. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg. 1996;22:39-43.
36. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48:249-253.
37. Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol Surg. 1998;24:1181-1183.
38. Hexsel DM, Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injection with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29:523-529.
39. Flynn TC, Carruthers A, Carruthers J. Surgical pearl: the use of the ultra-fine II short needle 0.3 cc insulin syringe for botulinum toxin injections. J Am Acad Dermatol. 2002; 46:931-933.
40. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998;24:1184-1186.
41. Gonnering RS. Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol. 1988;105:313-315.
42. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-1746.
43. Borodic F, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology. 1996;46:26-29.
44. Gaschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol. 1997;147:96-102.
45. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injection. Mov Disord. 1998;13: 150-154.
46. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2003;48:26-29.
47. Aoki KR. Preclinical update on BOTOX (botulinum toxin type A) purified neurotoxin preparations. Eur J Neurol. 1999;6(Suppl 4):S3-S10.
48. Merline AG, Spanoyannis A. BOTOX (Botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity [abstract]. Neurology. 1999;52:A521-A522.
49. Numann M, Yakovoleff A, Dorif F, et al. A randomized, double-masked crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249:57-63.
50. Racette B, Stambuk M, Perlmutter J. Secondary nonresponsiveness to new bulk botulinum toxin A. Mov Disord. 2002;17:1098-1100.
51. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-1188.
52. Markey AC. Dysport. Dermatol Clin. 2004;22:213-219.
53. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxin type A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4:15-18.
54. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MYOBLOC) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002;126:459-467.
55. Sadick NS. Botulinum toxin b: initial results. Dermatol Surg. 2002;28:817-821.
56. Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther. 2002;4:19-23.
57. Bauman L, Black L. Botulinum toxin type B (MYOBLOC). Dermatol Surg. 2003;29: 496-500.
58. Sadick NS, Matarasso SL. Comparison of botulinum toxin A and B in the treatment of facial rhytides. Dermatol Clin. 2004;22:221-226.
59. Pribitkin EA, Greco TM, Goode RL, et al. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. Arch Otolaryngol Head Neck Surg. 1997; 123:321-326.
60. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549-556.
61. Ekman P. Facial expression and emotion. Am Psychol. 1993;48:34-92.
62. Kane MAC. Classification of crow's feet patterns among Caucasian women: the key to individualizing treatment. Plast Reconstr Surg. 2003;112(5 suppl):33S-39S.
63. Carruthers A, Carruthers JDA. Advances in the use of botulinum toxin: special issue. Dermatol Surg. 2003;29:443-563.
64. Dayan SH. Botox. Facial Plast Surg Clin. 2003;11:431-555.
65. Rohrich RJ, Janis JE, Fagien S, et al. Cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;5(Suppl):1S-191S.
66. Klein AW. The clinical use of botulinum toxin. Dermatol Clin. 2004;22:131-230.
67. Moore P, Naumann M. Handbook of Botulinum Toxin Treatment, 2nd ed. Oxford: Blackwell Science; 2003.
68. Lipham WJ. Cosmetic and Clinical Applications of Botulinum Toxins. Thorofare, NJ: Slack; 2004.